Skip to content
Screener

Maravai LifeSciences Holdings, Inc. MRVI Q2 2026 earnings

Reported August 6, 2026 · After market close

Revenue$51.4MBeat by $2.8M
EPS-$0.02Beat by $0.02
Revenue estimate$48.7M
EPS estimate-$0.04
“Our second quarter results reflect the continued execution of our strategy and the momentum we are building across the business. Total revenue grew 9% year over year, with TriLink increasing 12% driven by strong demand for both Discovery and GMP consumables. Cygnus delivered 3% growth marking its fifth consecutive quarter of year-over-year growth. We also generated positive Adjusted EBITDA of $8.7 million, demonstrating the operating leverage of our business model and the progress we are making toward sustainable, profitable growth.”
Bernd Brust

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$43.7M
EPS estimate-$0.06

Financials

Q2 2026

Income statement

See full
Revenue$51.4M+8.5%
Gross profit$20.7M+166%
Operating income-$15.1M+77.2%
Net income-$12.4M+68.6%
EPS (diluted)-$0.08+70.4%

Balance sheet

See full
Cash & equivalents$70.6M-73.8%
Total debt$176.7M-52.4%
Total equity$204.6M-23.0%
Total assets$603.7M-32.7%

Cash flow

See full
Operating cash flow$4.0M+139%
CapEx$370.0K-87.1%
Free cash flow$3.6M+128%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$1.02B+151%
Enterprise value$1.13B+122%
P/S4.9×+3.0×

Profitability

See full
Gross margin34.9%+4.4pp
Operating margin-56.1%-21.3pp
Net margin-37.1%-13.6pp
FCF margin-17.2%—

Returns & leverage

See full
Return on equity-32.9%-9.4pp
Debt / equity0.9×-0.5×
Current ratio4.1×-1.1×

Segments

By geography

See full
Europe, the Middle East and Africa$10.5M+24.5%
Asia Pacific$9.3M+14.2%
Latin and Central America$386.0K+88.3%

FAQ

When did Maravai LifeSciences Holdings, Inc. report Q2 2026 earnings?
Maravai LifeSciences Holdings, Inc. (MRVI) reported Q2 2026 earnings on August 6, 2026 after market close.
What were Maravai LifeSciences Holdings, Inc.'s Q2 2026 revenue and EPS?
Maravai LifeSciences Holdings, Inc. reported revenue of $51.4M and eps of $-0.02 for Q2 2026.
Did Maravai LifeSciences Holdings, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $48.7M by $2.8M. EPS beat the consensus estimate of $-0.04 by $0.02.
How did Maravai LifeSciences Holdings, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 8.5% from $47.4M a year earlier and eps grew 75.0% from $-0.08.
Where can I find Maravai LifeSciences Holdings, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001823239-26-000056) and the 10-Q periodic report (0001823239-26-000059) directly on SEC EDGAR. The filing index links above go to sec.gov.